Free Trial

Revelation Biosciences (REVB) Competitors

Revelation Biosciences logo
$0.76 -0.01 (-1.44%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$0.76 0.00 (0.00%)
As of 07/3/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REVB vs. PRFX, ADTX, PBM, OGEN, GRI, QLGN, ONCO, JAGX, VRAX, and PTN

Should you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include PainReform (PRFX), Aditxt (ADTX), Psyence Biomedical (PBM), Oragenics (OGEN), GRI Bio (GRI), Qualigen Therapeutics (QLGN), Onconetix (ONCO), Jaguar Animal Health (JAGX), Virax Biolabs Group (VRAX), and Palatin Technologies (PTN). These companies are all part of the "pharmaceutical products" industry.

Revelation Biosciences vs. Its Competitors

PainReform (NASDAQ:PRFX) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Revelation Biosciences had 4 more articles in the media than PainReform. MarketBeat recorded 4 mentions for Revelation Biosciences and 0 mentions for PainReform. Revelation Biosciences' average media sentiment score of 0.19 beat PainReform's score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
PainReform Neutral
Revelation Biosciences Neutral

37.3% of PainReform shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 2.3% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PainReform's return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
PainReformN/A N/A N/A
Revelation Biosciences N/A -299.46%-115.36%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PainReform
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Revelation Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

PainReform is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PainReformN/AN/A-$14.59M-$147.33-0.01
Revelation BiosciencesN/AN/A-$15.04M-$102.61-0.01

PainReform has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500.

Summary

PainReform beats Revelation Biosciences on 7 of the 11 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REVB vs. The Competition

MetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.50M$2.91B$5.56B$9.03B
Dividend YieldN/A2.44%5.22%3.99%
P/E Ratio-0.0121.5627.6920.25
Price / SalesN/A241.84389.53161.89
Price / CashN/A42.7336.8958.10
Price / Book0.087.518.035.67
Net Income-$15.04M-$55.14M$3.18B$249.21M
7 Day PerformanceN/A4.61%2.93%3.28%
1 Month Performance-11.68%0.90%1.72%3.95%
1 Year Performance-97.26%5.40%34.39%20.98%

Revelation Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REVB
Revelation Biosciences
0.4583 of 5 stars
$0.76
-1.4%
N/A-97.3%$3.50MN/A-0.0110
PRFX
PainReform
0.7329 of 5 stars
$1.44
+2.1%
N/A-22.1%$2.84MN/A-0.014Positive News
ADTX
Aditxt
N/A$1.28
-3.8%
N/A-100.0%$2.82M$130K0.0060News Coverage
PBM
Psyence Biomedical
N/A$5.33
+8.6%
N/A-96.9%$2.80MN/A0.00N/AGap Up
OGEN
Oragenics
0.2144 of 5 stars
$3.82
-5.7%
N/A-95.1%$2.73M$40K-0.545Gap Down
GRI
GRI Bio
3.2929 of 5 stars
$1.29
+1.6%
$22.00
+1,605.4%
-94.6%$2.72MN/A-0.111Positive News
QLGN
Qualigen Therapeutics
N/A$3.41
-3.9%
N/A-76.7%$2.61M$4.98M0.0050
ONCO
Onconetix
0.2925 of 5 stars
$4.77
-1.2%
N/A-99.1%$2.57M$2.52M0.0012
JAGX
Jaguar Animal Health
1.8569 of 5 stars
$2.52
+0.8%
$60.00
+2,281.0%
-97.1%$2.55M$11.69M0.0050
VRAX
Virax Biolabs Group
2.854 of 5 stars
$0.79
+1.5%
$3.00
+278.9%
-29.1%$2.52M$160K0.005Positive News
PTN
Palatin Technologies
N/A$0.09
-44.6%
N/AN/A$2.45M$350K-0.0630Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:REVB) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners